The investigational mRNA-1010 influenza vaccine has undergone extensive clinical evaluation in a series of trials involving ...

GC Biopharma announced 09. Apr. 2025 that the Korean Ministry of Food and Drug Safety (MFDS) has approved its anthrax vaccine ...

Newseria nie ponosi odpowiedzialności za treści oraz inne materiały (np. infografiki, zdjęcia) przekazywane w „Biurze Prasowym”, których autorami są zarejestrowani użytkownicy tacy jak agencje PR, ...

Yong-in, South Korea Friday, April 11, 2025, 09:00 Hrs [IST] ...

The global vaccine CDMO market is set to witness a growth rate of 8% in the next 5 years. Increasing demand for vaccines, ...

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received five awards at the 2025 Asia-Pacific ...

It reported revenues of 38.41 million yuan in the first half of 2024 and a net loss of 903 million yuan, hit by falling ...

This project not only would expand our portfolio but also would reinforce the C1 platform's proven ability to rapidly develop and produce cost- effective recombinant protein vaccine antigens.

Founded in 1987 in the US, Gale Smith – VP of vaccine development at Novavax – invented the technique of using insect cells for producing recombinant protein vaccines. A further milestone came ...

Researchers have engineered Lyme bacterial protein, CspZ, to produce a robust immune response in mice for vaccine development.

This project not only would expand our portfolio but also would reinforce the C1 platform's proven ability to rapidly develop and produce cost- effective recombinant protein vaccine antigens.